MTNB (MTNB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MTNB (MTNB) trades at $0.2804 with AI Score 26/100 (Grade F). Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in lipid nanocrystal (LNC) technology for drug delivery. Market cap: $1.56M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 4, 2026Analyst Coverage for MTNB: MTNB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MTNB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MTNB: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MTNB (MTNB) Healthcare & Pipeline Overview
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company leveraging its lipid nanocrystal (LNC) platform to develop novel therapies. Their focus is on addressing unmet needs in cardiovascular, metabolic, and infectious diseases, positioning them in a competitive but high-potential biotechnology landscape.
What Is the Investment Thesis for MTNB?
Matinas BioPharma Holdings, Inc. presents a high-risk, high-reward investment opportunity centered on its LNC platform technology. The company's value hinges on the successful clinical development and potential commercialization of its lead product candidates, particularly LYPDISO, MAT2203, and MAT2501. Positive Phase II and Phase III trial results for these candidates could serve as significant catalysts, driving stock appreciation. The collaborations with NIAID and Genentech also provide validation of the LNC platform and potential for future revenue streams. However, the company's small market capitalization of $1.56M and limited resources pose substantial financial risks. Failure to secure additional funding or achieve clinical milestones could negatively impact the company's prospects. The biotechnology sector is highly competitive, and Matinas BioPharma faces competition from larger, more established companies with greater resources. Investors should carefully assess the potential upside against the inherent risks associated with clinical-stage biopharmaceutical companies.
Based on FMP financials and quantitative analysis
MTNB Key Highlights
- LYPDISO targets a large market in cardiovascular and metabolic conditions, offering significant revenue potential if approved.
- MAT2203 addresses a critical unmet need in preventing invasive fungal infections, with Phase II clinical trials underway.
- MAT2501 aims to combat multidrug-resistant bacterial infections, a growing global health concern.
- Research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir validates the LNC platform.
- Feasibility collaboration with Genentech, Inc. for the development of oral formulations provides potential for future partnerships and revenue streams.
Who Are MTNB's Competitors?
MTNB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.78 | -2.57% | $161B | 94 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| BLRX BioLineRx Ltd. | $2.92 | +3.18% | $12.7M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.02 | -1.95% | $165M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MTNB's Key Strengths?
- Proprietary lipid nanocrystal (LNC) platform technology
- Diverse product pipeline targeting multiple therapeutic areas
- Research collaborations with leading institutions
- Oral formulations offering improved patient compliance
What Are MTNB's Weaknesses?
- Limited financial resources
- Small market capitalization
- Dependence on clinical trial outcomes
- Limited commercialization experience
What Could Drive MTNB Stock Higher?
- Phase II clinical trial results for MAT2203 in the prevention of invasive fungal infections.
- Initiation of Phase III clinical trials for LYPDISO in the treatment of cardiovascular and metabolic conditions.
- Progress in research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir.
- Advancement of MAT2501 through clinical development for the treatment of multidrug-resistant bacterial infections.
What Are the Key Risks for MTNB?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive clinical trial results for its product candidates.
- Inability to secure additional funding to support its operations and research initiatives.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory delays or setbacks in the approval process for its product candidates.
- Dependence on the success of its LNC platform technology.
What Are the Growth Opportunities for MTNB?
- LYPDISO Commercialization: Successful completion of clinical trials and subsequent FDA approval for LYPDISO could unlock a substantial market opportunity in the treatment of cardiovascular and metabolic conditions. The market for omega-3 fatty acid-based therapies is significant, with potential for LYPDISO to capture a share of this market if it demonstrates superior efficacy and safety. Timeline: Potential FDA submission within the next 2-3 years, pending positive clinical trial results.
- MAT2203 Expansion: Advancing MAT2203 through Phase III clinical trials and securing regulatory approval could address a critical unmet need in the prevention of invasive fungal infections, particularly in immunocompromised patients. The market for antifungal therapies is growing, driven by the increasing prevalence of fungal infections and the emergence of drug-resistant strains. Timeline: Phase III trials initiation within the next year, with potential for regulatory submission in 3-4 years.
- MAT2501 Development: Further development of MAT2501 for the treatment of multidrug-resistant bacterial infections represents a significant growth opportunity, given the increasing global threat of antibiotic resistance. The market for novel antibiotics is expanding, driven by the need for effective treatments against resistant bacteria. Timeline: Seeking strategic partnerships to advance clinical development, with potential for Phase II trials within the next 2 years.
- LNC Platform Expansion: Leveraging the LNC platform to develop oral formulations of other existing and novel drugs could create new revenue streams and expand the company's product pipeline. The collaboration with Genentech provides a potential avenue for exploring new applications of the LNC platform. Timeline: Ongoing research and development efforts, with potential for new product candidates within the next 3-5 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its product candidates could provide Matinas BioPharma with access to additional funding, expertise, and resources. These partnerships could also accelerate the development and commercialization of its products and expand its market reach. Timeline: Ongoing business development efforts, with potential for new partnerships within the next 1-2 years.
What Opportunities Does MTNB Have?
- Successful clinical development and commercialization of its product candidates
- Expansion of the LNC platform to new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Growing market for novel drug delivery technologies
What Threats Does MTNB Face?
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent infringement
What Are MTNB's Competitive Advantages?
- Proprietary lipid nanocrystal (LNC) platform technology.
- Patent protection for its LNC platform and product candidates.
- Research collaborations with leading institutions.
- First-mover advantage in developing oral formulations of certain drugs.
What Does MTNB Do?
Matinas BioPharma Holdings, Inc., incorporated in 2013 and based in Bedminster, New Jersey, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative product candidates. The company's core technology is its proprietary lipid nanocrystal (LNC) platform, which enables the delivery of various therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. This platform aims to improve the bioavailability and therapeutic efficacy of existing and novel drugs. Matinas BioPharma's lead product candidate, LYPDISO, is a prescription-only omega-3 free fatty acid-based composition targeting cardiovascular and metabolic conditions. Additionally, the company is developing MAT2203, an oral formulation of amphotericin B currently in Phase II clinical trials for the prevention of invasive fungal infections in immunocompromised patients. MAT2501, an orally administered formulation of amikacin, has completed Phase I clinical trials and is being developed to treat multidrug-resistant bacterial infections. Matinas BioPharma also has research collaborations with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. With a small team of 3 employees, Matinas BioPharma focuses on strategic partnerships and clinical advancements to drive value.
What Products and Services Does MTNB Offer?
- Develops products using its lipid nanocrystal (LNC) platform technology.
- Utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
- Focuses on treatments for cardiovascular and metabolic conditions.
- Offers an oral formulation of amphotericin B for the prevention of invasive fungal infections.
- Provides an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin.
- Collaborates with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir.
- Has a feasibility collaboration with Genentech, Inc. for the development of oral formulations.
How Does MTNB Make Money?
- Develops pharmaceutical products using its proprietary LNC platform.
- Out-licenses or co-develops its products with larger pharmaceutical companies.
- Generates revenue through research collaborations and partnerships.
- Aims to commercialize its products through direct sales or partnerships, pending regulatory approvals.
What Industry Does MTNB Operate In?
Matinas BioPharma operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant financial risks. The market for novel drug delivery technologies is expanding, driven by the need to improve the efficacy and safety of existing and new therapies. Companies like Matinas BioPharma, with its LNC platform, are positioned to capitalize on this trend. However, the industry is dominated by larger pharmaceutical companies with greater resources for research, development, and commercialization. Success depends on securing funding, achieving clinical milestones, and navigating the complex regulatory landscape.
Who Are MTNB's Key Customers?
- Pharmaceutical companies seeking novel drug delivery technologies.
- Patients with cardiovascular and metabolic conditions.
- Patients at risk of invasive fungal infections.
- Patients with multidrug-resistant bacterial infections.
FY2026 estForward Outlook
Wall Street analysts project MTNB revenue of about $93.3M for fiscal 2026, with EPS near $-5.00.
F-Score 1/9Financial Health
MTNB's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MTNB Valuation & Market Position
With a $1.56M market cap, MTNB sits in the micro-cap segment of the market. Relative to its peer group, MTNB's quantitative score of 26/100 is below the peer average of 76/100.
MTNB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- MTNB insiders seem to be showing confidence lately; their recent activity suggests they believe in the company's future prospects.
- The buzz around MTNB in the community is generally positive; people are talking about its potential for growth and innovation.
- MTNB is gaining recognition for its strategic moves in the market; it's perceived as a company that's actively shaping its own success.
- Market developments appear to favor MTNB's business model; the current environment could provide tailwinds for its expansion.
Bear Case
- There's some concern in the community about MTNB's long-term strategy; some people question whether it's truly sustainable.
- MTNB's recent performance hasn't fully met market expectations; this has led to some skepticism about its ability to deliver.
- Insider activity, while generally positive, has some mixed signals; a few sales have raised questions among investors.
- The overall market sentiment is cautious; this could create headwinds for MTNB, regardless of its individual strengths.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MTNB Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Jul 14, 2026
-
Nasdaq Surges Over 100 Points; Bank of America Earnings Top Views
benzinga · Jul 14, 2026
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jul 14, 2026
-
Top Premarket Decliners
MT Newswires · Jul 14, 2026
MTNB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MTNB.
Price Targets
Wall Street price target analysis for MTNB.
MTNB MoonshotScore
What does this score mean?
The MoonshotScore rates MTNB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Leadership: Jerome D. Jabbour
CEO
Jerome D. Jabbour serves as the Chief Executive Officer of Matinas BioPharma Holdings, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in companies focused on drug development and commercialization. Jabbour's expertise spans strategic planning, business development, and financial management within the healthcare sector. He is responsible for guiding Matinas BioPharma's strategic direction and overseeing the company's operations.
Track Record: Under Jerome D. Jabbour's leadership, Matinas BioPharma has focused on advancing its LNC platform and progressing its clinical pipeline. Key milestones include the advancement of LYPDISO, MAT2203, and MAT2501 through clinical trials, as well as securing research collaborations with NIAID and Genentech. Jabbour has also been instrumental in raising capital to fund the company's operations and research initiatives.
MTNB Healthcare Stock: Key Questions Answered
What does the AI Score mean for MTNB?
MTNB holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in lipid nanocrystal (LNC) technology for drug delivery. Their pipeline focuses on treatments …
What does Matinas BioPharma Holdings, Inc. do?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies for unmet medical needs. The company's core technology is its proprietary lipid nanocrystal (LNC) platform, which enables the delivery of various therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
What do analysts say about MTNB stock?
Analyst coverage of Matinas BioPharma Holdings, Inc. is limited, reflecting its small market capitalization and early stage of development. The consensus view is that MTNB represents a high-risk, high-reward investment opportunity. Key valuation metrics are difficult to assess given the company's lack of revenue and reliance on future clinical milestones.
What are the main risks for MTNB?
Matinas BioPharma Holdings, Inc. faces several significant risks inherent to clinical-stage biopharmaceutical companies. These include the risk of clinical trial failures, which could halt the development of its product candidates and negatively impact its stock price. The company also faces regulatory risks, as the FDA approval process is complex and uncertain.
What are the key factors to evaluate for MTNB?
MTNB holds an AI score of 26/100 (low). Not financial advice.
How frequently does MTNB data refresh on this page?
MTNB's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MTNB's recent stock price performance?
MTNB moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary lipid nanocrystal (LNC) platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MTNB overvalued or undervalued right now?
MTNB has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MTNB before investing?
Before investing in MTNB, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and due diligence.